The new Alzheimer's disease drug made by Eisai Inc. and Biogen Inc. is capable of slowing cognitive decline by 27%, as confirmed by a peer-reviewed study, yet was associated with brain bleeds in a significant number of patients.
The study was published in the New England Journal of Medicine on Tuesday, when Eisai also presented the data at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco. The data were heavily anticipated, since Eisai and Biogen (Nasdaq: BIIB)…
